CA2473987C - Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases - Google Patents

Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases Download PDF

Info

Publication number
CA2473987C
CA2473987C CA2473987A CA2473987A CA2473987C CA 2473987 C CA2473987 C CA 2473987C CA 2473987 A CA2473987 A CA 2473987A CA 2473987 A CA2473987 A CA 2473987A CA 2473987 C CA2473987 C CA 2473987C
Authority
CA
Canada
Prior art keywords
peptide
amyloid
amino acid
peptides
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2473987A
Other languages
English (en)
French (fr)
Other versions
CA2473987A1 (en
Inventor
Ehud Gazit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tel Aviv University Future Technology Development LP
Original Assignee
Tel Aviv University Future Technology Development LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/235,852 external-priority patent/US20040052928A1/en
Application filed by Tel Aviv University Future Technology Development LP filed Critical Tel Aviv University Future Technology Development LP
Publication of CA2473987A1 publication Critical patent/CA2473987A1/en
Application granted granted Critical
Publication of CA2473987C publication Critical patent/CA2473987C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/585—Calcitonins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2473987A 2002-01-31 2003-01-30 Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases Expired - Fee Related CA2473987C (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US35257802P 2002-01-31 2002-01-31
US60/352,578 2002-01-31
US39226602P 2002-07-01 2002-07-01
US60/392,266 2002-07-01
US10/235,852 2002-09-06
US10/235,852 US20040052928A1 (en) 2002-09-06 2002-09-06 Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US43645302P 2002-12-27 2002-12-27
US60/436,453 2002-12-27
PCT/IL2003/000079 WO2003063760A2 (en) 2002-01-31 2003-01-30 Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases

Publications (2)

Publication Number Publication Date
CA2473987A1 CA2473987A1 (en) 2003-08-07
CA2473987C true CA2473987C (en) 2013-11-19

Family

ID=27671045

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2473987A Expired - Fee Related CA2473987C (en) 2002-01-31 2003-01-30 Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases

Country Status (6)

Country Link
EP (1) EP1534310A4 (enExample)
JP (1) JP2006506942A (enExample)
KR (1) KR20040081165A (enExample)
AU (1) AU2003207973A1 (enExample)
CA (1) CA2473987C (enExample)
WO (1) WO2003063760A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040052928A1 (en) 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US7781396B2 (en) 2002-01-31 2010-08-24 Tel Aviv University Future Technology Development L.P. Peptides directed for diagnosis and treatment of amyloid-associated disease
US7491699B2 (en) 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
WO2004060791A1 (en) 2003-01-07 2004-07-22 Ramot At Tel Aviv University Ltd. Peptide nanostructures encapsulating a foreign material and method of manufacturing same
CN101415724B (zh) 2003-06-30 2015-12-02 特拉维夫大学未来科技开发有限公司 肽、抗肽抗体以及用它们来诊断和治疗淀粉样蛋白相关疾病的方法
WO2005031362A2 (en) 2003-10-02 2005-04-07 Ramot At Tel Aviv University Ltd. Novel antibacterial agents and methods of identifying and utilizing same
WO2006013552A2 (en) 2004-08-02 2006-02-09 Ramot At Tel Aviv University Ltd. Articles of peptide nanostructures and method of forming the same
US10004828B2 (en) 2005-10-11 2018-06-26 Romat at Tel-Aviv University Ltd. Self-assembled Fmoc-ff hydrogels
DE112007001030T5 (de) * 2006-04-28 2009-02-26 Kagoshima University Amyloid-ß-Fibrillogenese-inhibierendes Peptid
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
MX2012010470A (es) 2010-03-10 2012-10-09 Probiodrug Ag Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5).
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
JP5848768B2 (ja) 2010-10-29 2016-01-27 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッドＲａｍｏｔ Ａｔ Ｔｅｌ Ａｖｉｖ Ｕｎｉｖｅｒｓｉｔｙ Ｌｔｄ． インドール誘導体及びその製造方法
RU2013126706A (ru) 2010-11-15 2014-12-27 Рамот Ат Тель-Авив Юниверсити Лтд. Дипептидные аналоги для лечения состояний, ассоциированных с образованием амилоидных фибрилл
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
JP6225189B2 (ja) * 2012-09-12 2017-11-01 ニューリミューン ホールディング エイジー ヒト膵島アミロイドポリペプチド（ｈＩＡＰＰ）特異的抗体およびその使用
KR101956302B1 (ko) * 2016-11-30 2019-03-11 연세대학교 산학협력단 세포 내부 pH 감응성 융합 펩티드 및 이를 유효성분으로 포함하는 단백질의 비정상적인 응집 또는 미스폴딩과 관련된 질환을 예방 또는 치료하기 위한 약학 조성물
WO2019033099A1 (en) 2017-08-11 2019-02-14 University Of Kentucky Research Foundation ANTI-NEURODENERATIVE THERAPEUTIC COMPOUND, METHOD OF MANUFACTURE AND USE
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
TW202144387A (zh) * 2020-02-11 2021-12-01 美商聯合生物醫學公司 針對胰島澱粉樣多肽（iapp）的胜肽免疫原及其預防和治療與聚集iapp相關疾病的製劑
CN120457342A (zh) * 2022-12-05 2025-08-08 神经免疫有限公司 环状化合物及环状化合物在用于检测抗体的测定中的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6344895A (ja) * 1986-08-13 1988-02-25 Kyowa Hakko Kogyo Co Ltd 抗アミロイドａ蛋白質単クロ−ン性抗体
AU7261994A (en) * 1993-07-19 1995-02-20 Resolution Pharmaceuticals Inc. Hydrazino-type radionuclide chelators having an n3s configuration
US6303567B1 (en) * 1995-03-14 2001-10-16 Praecis Pharmaceuticals, Inc . Modulators of β-amyloid peptide aggregation comprising D-amino acids
US6426075B1 (en) * 1996-11-06 2002-07-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Protease-activatable pseudomonas exotoxin A-like proproteins
JP2000193661A (ja) * 1998-12-25 2000-07-14 Tokyo Rika Kikai Kk 痴呆症の検査方法

Also Published As

Publication number Publication date
JP2006506942A (ja) 2006-03-02
WO2003063760A2 (en) 2003-08-07
KR20040081165A (ko) 2004-09-20
EP1534310A2 (en) 2005-06-01
EP1534310A4 (en) 2006-05-31
AU2003207973A1 (en) 2003-09-02
WO2003063760A3 (en) 2005-02-10
CA2473987A1 (en) 2003-08-07

Similar Documents

Publication Publication Date Title
AU2004251522C1 (en) Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
US8012929B2 (en) Peptides directed for diagnosis and treatment of amyloid-associated diseases
US8563273B2 (en) Method of screening for compounds that disaggregate amyloid aggregates
KR20040081165A (ko) 펩타이드 항체 및 이를 이용한 아밀로이드-관련 질환의진단 및 치료 방법
US20050020809A1 (en) Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
WO2005090388A1 (en) Alpha helical mimics, their uses and methods for their production
US20160168212A1 (en) Compositions for treatment of neurodegenerative diseases
AU2004203461B2 (en) Peptides Antibodies Directed Thereagainst and Methods Using Same for Diagnosing and Treating Amyloid-Associated Diseases
IL210418A (en) Peptides for treating amyloid-associated diseases
US20130252905A1 (en) Plif multimeric peptides and uses thereof
HK1129685A (en) Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
IL172788A (en) Use of peptides in the manufacture of medicaments for treating amyloid-associated diseases
AU2005222732B2 (en) Alpha helical mimics, their uses and methods for their production

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20180130